Treatment of Major Depressive Disorders with Generic Duloxetine and Paroxetine: a Multi-centered, Double-blind, Double-dummy, Randomized Controlled Clinical Trial

Overview

Journal Shanghai Arch Psychiatry

Specialty Psychiatry

Date 2015 Nov 10

PMID 26549959

Citations 2

Authors

Zhiyang Wang

Xiufeng Xu

Qingrong Tan

Keqing Li

Cui Ma

Shiping Xie

Chengge Gao

Gang Wang

Huafang Li

Affiliations

Soon will be listed here.

Abstract

Background: This study is a pre-registration trial of generic duloxetine that was approved by the China Food and Drug Administration (approval number: 2006L01603).

Aims: Compare the treatment efficacy and safety of generic duloxetine to that of paroxetine in patients with major depressive disorders (MDD).

Methods: This was a double-dummy, double-blind, multicenter, positive drug (paroxetine), parallel randomized controlled clinical trial. The 299 patients with MDD recruited for the study were randomly assigned to use duloxetine (n=149; 40-60 mg/d) or paroxetine (n=150; 20 mg/d) for 8 weeks. The Hamilton Depression rating scale (HAMD-17) was administered at baseline and 1, 2, 4, 6, and 8 weeks after starting treatment. Remission was defined as a HAMD-17 score below 8 at the end of the trial, and treatment effectiveness was defined as a decrease in baseline HAMD-17 score of at least 50% by the end of the trial. Safety was assessed based on the reported prevalence and severity of side effects and changes in laboratory and electrocardiographic findings. Three patients in the duloxetine group dropped out before starting medication, so results were analyzed using a modified intention-to-treat (ITT) method with 146 in the experimental group and 150 in the control group.

Results: Both groups experienced 29 dropouts during the 8-week trial. HAMD-17 scores decreased significantly from baseline throughout the trial in both groups. Based on the ITT analysis, at the end of the trial there was no significant difference between the duloxetine group and the paroxetine group in effectiveness (67.1% v. 71.3%, X(2)=0.62 p=0.433), remission rate (41.1% v. 51.3%, X(2)=3.12, p=0.077), or in the incidence of side effects (56.8% v. 54.7%, X(2)=0.14, p=0.705).

Conclusions: Generic duloxetine is as effective and safe as paroxetine in the acute treatment of patients with MDD who seek care at psychiatric outpatient departments in China.

Citing Articles

Conditional power of antidepressant network meta-analysis.

Holper L BMC Psychiatry. 2021; 21(1):129.

PMID: 33673822 PMC: 7934491. DOI: 10.1186/s12888-021-03094-5.

Systems Pharmacology Based Study of the Molecular Mechanism of SiNiSan Formula for Application in Nervous and Mental Diseases.

Shen X, Zhao Z, Luo X, Wang H, Hu B, Guo Z Evid Based Complement Alternat Med. 2017; 2016:9146378.

PMID: 28058059 PMC: 5183803. DOI: 10.1155/2016/9146378.

References

Lecrubier Y . The burden of depression and anxiety in general medicine. J Clin Psychiatry. 2002; 62 Suppl 8:4-9; discussion 10-1. View

Phillips M, Zhang J, Shi Q, Song Z, Ding Z, Pang S . Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey. Lancet. 2009; 373(9680):2041-53. DOI: 10.1016/S0140-6736(09)60660-7. View

Kirwin J, Goren J . Duloxetine: a dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder. Pharmacotherapy. 2005; 25(3):396-410. DOI: 10.1592/phco.25.3.396.61600. View

Westanmo A, Gayken J, Haight R . Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. Am J Health Syst Pharm. 2005; 62(23):2481-90. DOI: 10.2146/ajhp050006. View

Martinez J, Katon W, Greist J, Kroenke K, Thase M, Meyers A . A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode. Int Clin Psychopharmacol. 2011; 27(1):17-26. DOI: 10.1097/YIC.0b013e32834ce11b. View

Rush A . STAR*D: what have we learned?. Am J Psychiatry. 2007; 164(2):201-4. DOI: 10.1176/ajp.2007.164.2.201. View

Kornstein S, Russell J, Spann M, Crits-Christoph P, Ball S . Duloxetine in the treatment of generalized anxiety disorder. Expert Rev Neurother. 2009; 9(2):155-65. DOI: 10.1586/14737175.9.2.155. View

Arnold L, Zhang S, Pangallo B . Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study. Clin J Pain. 2012; 28(9):775-81. DOI: 10.1097/AJP.0b013e3182510295. View

Gaynor P, Gopal M, Zheng W, Martinez J, Robinson M, Marangell L . A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms. Curr Med Res Opin. 2011; 27(10):1849-58. DOI: 10.1185/03007995.2011.609539. View

10.

Lee P, Shu L, Xu X, Wang C, Lee M, Liu C . Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. Psychiatry Clin Neurosci. 2007; 61(3):295-307. DOI: 10.1111/j.1440-1819.2007.01666.x. View

11.

Hirschfeld R . The epidemiology of depression and the evolution of treatment. J Clin Psychiatry. 2012; 73 Suppl 1:5-9. DOI: 10.4088/JCP.11096su1c.01. View

12.

Carter N, McCormack P . Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009; 23(6):523-41. DOI: 10.2165/00023210-200923060-00006. View

13.

Whiteford H, Degenhardt L, Rehm J, Baxter A, Ferrari A, Erskine H . Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013; 382(9904):1575-86. DOI: 10.1016/S0140-6736(13)61611-6. View

14.

Gonda X, Fountoulakis K, Kaprinis G, Rihmer Z . Prediction and prevention of suicide in patients with unipolar depression and anxiety. Ann Gen Psychiatry. 2007; 6:23. PMC: 2031887. DOI: 10.1186/1744-859X-6-23. View

15.

Goldstein D, Lu Y, Detke M, Wiltse C, Mallinckrodt C, Demitrack M . Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004; 24(4):389-99. DOI: 10.1097/01.jcp.0000132448.65972.d9. View

16.

Ball S, Desaiah D, Zhang Q, Thase M, Perahia D . Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary. Drugs Context. 2014; 2013:212245. PMC: 3884746. DOI: 10.7573/dic.212245. View

17.

Brunton S, Wang F, Edwards S, Crucitti A, Ossanna M, Walker D . Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Drug Saf. 2010; 33(5):393-407. DOI: 10.2165/11319200-000000000-00000. View

18.

Thase M, Pritchett Y, Ossanna M, Swindle R, Xu J, Detke M . Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol. 2007; 27(6):672-6. DOI: 10.1097/jcp.0b013e31815a4412. View

19.

Detke M, Lu Y, Goldstein D, Hayes J, Demitrack M . Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002; 63(4):308-15. DOI: 10.4088/jcp.v63n0407. View